Clinical Relevance and Interplay between miRNAs in Influencing Glioblastoma Multiforme Prognosis

Area of Science:

• Neuro-oncology
• Molecular Biology
• Genetics

Background:

• Glioblastoma multiforme (GBM) treatment involves surgery, radiotherapy, and temozolomide (TMZ).
• Methylguanine-DNA methyltransferase (MGMT) methylation predicts TMZ response, but some MGMT-unmethylated GBMs show favorable outcomes.
• Additional biomarkers for TMZ response in GBM are needed.

Purpose of the Study:

• To investigate the clinical relevance of six microRNAs (miRNAs) in GBM patients receiving TMZ.
• To evaluate miRNAs as potential markers for TMZ response and survival.
• To explore the interplay between specific miRNAs and patient outcomes.

Main Methods:

• miRNA expression was evaluated in 112 IDH-wildtype GBM samples using commercial assays.
• The study analyzed the expression levels and interplay of miR-181c, miR-181d, miR-21, miR-195, miR-196b, and miR-648.
• miRNA expression was correlated with patient clinical outcomes, including overall survival (OS).

Main Results:

• A significant association was found between the expression levels of the analyzed miRNAs.
• The combination of low miR-648 and low miR-181c or miR-181d expression was linked to a worse prognosis.
• Specific miRNA pairs demonstrated a correlation with overall survival in GBM patients treated with TMZ.

Conclusions:

• Specific miRNA pairs can influence survival in glioblastoma multiforme patients treated with temozolomide.
• Low expression of miR-648 combined with miR-181c or miR-181d may serve as a prognostic marker.
• Further research into miRNA roles could refine glioblastoma treatment strategies.